サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414400

転移性乳がん治療の世界市場レポート 2024年

Metastatic Breast Cancer Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
転移性乳がん治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

転移性乳がん治療の市場規模は近年急速に拡大しています。2023年の177億4,000万米ドルから2024年には199億5,000万米ドルへと、CAGR12.4％で拡大します。過去の期間に見られた成長は、全身療法の進歩、臨床試験の成功、診断ツールの改善、患者支援と教育における努力に起因しています。

転移性乳がん治療の市場規模は今後数年で急成長が見込まれます。2028年にはCAGR11.2％で305億1,000万米ドルに成長します。予測期間中に予想される成長は、標的療法の進歩、個別化医療の動向、罹患率の増加、革新的な治療法への世界のアクセスの改善に起因すると考えられます。この予測期間に予想される主な動向には、モニタリングのためのリキッドバイオプシーの使用、患者中心のアプローチ、支持療法の強化、革新的治療へのアクセス拡大、共同研究イニシアチブなどが含まれます。

予想される乳がん罹患率の上昇が、当面の転移性乳がん治療市場の成長を牽引するとみられます。乳がんは、乳房の細胞から発生するがんの一種で、異常な細胞が制御不能な成長を遂げて腫瘍を形成することで発症します。この発生は、遺伝的要因、ホルモンバランスの乱れ、ライフスタイル、環境要素に影響されます。転移性乳がん治療は、乳がんの有病率の管理、治療成績の向上、進行期の病気に直面している人々の生活の質の向上に貢献しています。2023年9月に米国がん協会が発表した報告書によると、同年には約297,790人の女性が浸潤性乳がんと診断され、さらに55,720人の乳管がん（DCIS）が新たに発症すると予測されています。また、2023年には約43,700人の女性が乳がんで命を落とすと推定されています。その結果、乳がん有病率の増加が転移性乳がん治療市場成長の原動力となっています。

老人人口の急増は、転移性乳がん治療市場の成長を後押しします。一般的に65歳以上と定義される老年人口は増加傾向にあり、転移性乳がん治療の需要に大きく貢献しています。年齢が転移性乳がん発症の顕著なリスク要因であることから、この層特有のニーズへの対応が市場の持続的成長にとって極めて重要になります。世界保健機関（WHO）の2022年10月の報告書に示されているように、2030年までに世界の6人に1人が60歳以上になると予測されています。さらに、2050年にはこの年齢層に該当する人が世界で21億人になると予測されています。従って、老人人口の増加が転移性乳がん治療市場成長の重要な促進要因となっています。

北米は、2023年の転移性乳がん治療市場において最大の地域でした。アジア太平洋は、予測期間中、世界の転移性乳がん治療市場で最も急成長している地域になると予測されています。転移性乳がん治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の転移性乳がん治療市場、治療法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 化学療法
  • 放射線治療
  • 生物学的標的療法
  • 乳腺外科
  • ホルモン療法
  • 世界の転移性乳がん治療市場、分子タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • モノクローナル抗体
  • ペプチド
  • ポリマー
  • 低分子
  • 遺伝子治療
  • 世界の転移性乳がん治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 世界の転移性乳がん治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック
  • 外来手術センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の転移性乳がん治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の転移性乳がん治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 転移性乳がん治療市場の競合情勢
  • 転移性乳がん治療市場の企業プロファイル
    • Pfizer Inc.
    • AstraZeneca plc
    • Novartis AG
    • Gilead Science Inc.
    • Eli Lilly &Co.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11910

“Metastatic Breast Cancer Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic breast cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic breast cancer treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The metastatic breast cancer treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Therapy Type: Chemotherapy; Radiation Therapy; Biologic Targeted Therapy; Breast Surgery; Hormone Therapy
  • 2) By Molecule Type: Monoclonal Antibody; Peptides; Polymer; Small Molecule; Gene Therapy
  • 3) By Route Of Administration: Oral; Parenteral
  • 4) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Novartis AG; Gilead Science Inc.; Eli Lilly & Co.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Metastatic breast cancer treatment involves medical interventions and therapies aimed at managing breast cancer that has spread (metastasized) from the breast to other parts of the body. The primary objectives of treating metastatic breast cancer are to maximize the patient's survival duration with the disease.

The main types of metastatic breast cancer treatment include chemotherapy, radiation therapy, biologic-targeted therapy, breast surgery, and hormone therapy. Chemotherapy utilizes drugs designed to kill or inhibit the growth of rapidly dividing cells, including cancer cells. It achieves this by targeting the DNA or essential processes of these cells. In the context of metastatic breast cancer treatment, chemotherapy aims to kill or control cancer cells throughout the body, utilizing specific drugs that circulate in the bloodstream. Various types of molecules, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy, are administered through oral or parenteral routes by healthcare facilities such as hospitals, clinics, ambulatory surgical centers, and other end-users.

The metastatic breast cancer treatment market research report is one of a series of new reports from The Business Research Company that provides metastatic breast cancer treatment market statistics, including the metastatic breast cancer treatment industry global market size, regional shares, competitors with a metastatic breast cancer treatment market share, detailed metastatic breast cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic breast cancer treatment industry. This metastatic breast cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic breast cancer treatment market size has grown rapidly in recent years. It will grow from $17.74 billion in 2023 to $19.95 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed in the historical period can be attributed to advancements in systemic therapies, successful outcomes in clinical trials, improvements in diagnostic tools, and efforts in patient advocacy and education.

The metastatic breast cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $30.51 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated growth in the forecast period can be attributed to advancements in targeted therapies, trends in personalized medicine, an increase in incidence rates, and improved global access to innovative therapies. Major trends expected in this forecast period include the use of liquid biopsy for monitoring, patient-centric approaches, enhanced supportive care, expanded access to innovative therapies, and collaborative research initiatives.

The anticipated rise in breast cancer prevalence is set to drive the growth of the metastatic breast cancer treatment market in the foreseeable future. Breast cancer, a type of cancer originating in the cells of the breast, develops as abnormal cells undergo uncontrolled growth, forming tumors. This occurrence is influenced by genetic factors, hormonal imbalances, lifestyle, and environmental elements. Metastatic breast cancer treatment contributes to managing the prevalence of breast cancer, enhancing outcomes, and improving the quality of life for individuals facing advanced-stage disease. As per a September 2023 report from the American Cancer Society, approximately 297,790 women are expected to be diagnosed with invasive breast cancer in the same year, with an additional 55,720 new cases of ductal carcinoma in situ (DCIS) projected. The report also estimates that around 43,700 women will succumb to breast cancer in 2023. Consequently, the increasing prevalence of breast cancer stands as a driving force behind the growth of the metastatic breast cancer treatment market.

The surge in the geriatric population is poised to bolster the growth of the metastatic breast cancer treatment market. The geriatric population, typically defined as individuals aged 65 or older, is witnessing an upward trend, contributing significantly to the demand for metastatic breast cancer treatments. With age being a notable risk factor for developing metastatic breast cancer, addressing the unique needs of this demographic becomes crucial for sustained market growth. As indicated in an October 2022 report from the World Health Organization (WHO), it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The estimate further predicts that by 2050, there will be 2.1 billion people worldwide falling into this age bracket. Hence, the increase in the geriatric population emerges as a key driver for the growth of the metastatic breast cancer treatment market.

The introduction of advanced therapeutic remedies is a prominent trend gaining traction in the metastatic breast cancer treatment market. Major companies in this market are actively advancing therapeutic remedies as part of their strategy to maintain a competitive position. An example is BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that launched Palbociclib, branded as 'BDPALBO' in India. BDPALBO, a generic version of palbociclib, offers a cost-effective treatment option for patients diagnosed with metastatic breast cancer.

Innovation in product development, particularly monoclonal antibodies (mAbs), is a key focus for major companies operating in the metastatic breast cancer treatment market. Monoclonal antibodies, laboratory-produced molecules mimicking the immune system's ability to combat pathogens, are gaining prominence. Roche Pharma, a Switzerland-based pharmaceutical company, introduced PHESGO in India in May 2022. PHESGO, a groundbreaking formulation, combines two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), along with hyaluronidase, providing a streamlined treatment approach for both early and metastatic HER2-positive breast cancer. This innovation aims to enhance treatment efficiency and patient convenience, incorporating the benefits of multiple monoclonal antibodies into a more accessible and patient-friendly delivery method.

In April 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enhances Pfizer's oncology portfolio by incorporating antibody-drug conjugate (ADC) technology for the development of drug programs. Seagen Inc., a US-based biotechnology company, is known for its contributions to metastatic triple-negative breast cancer treatment.

Major companies operating in the metastatic breast cancer treatment market report are Pfizer Inc., AstraZeneca plc, Novartis AG, Gilead Science Inc., Eli Lilly & Co., Merck & Co. Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer Aktiengesellschaft ., Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Applied Molecular Genetics Inc., Aslan Pharmaceuticals Pte. Ltd., AbbVie Inc., Eisai Co. ltd., Seattle Genetics Inc., Immunomedics Inc., Genentech Inc., MacroGenics Inc., Daiichi Sankyo Company Lmited, Takeda Pharmaceutical Company Lmited, Sanofi S.A., Celgene Corporation, Exelixis Inc., Array BioPharma Inc., Athenex Inc., BioMarin Pharmaceutical Inc., Clovis Oncology Inc., Cyclacel Pharmaceuticals Inc., Immunovative Therapies Ltd., Inovio Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Mersana Therapeutics Inc., Myriad Genetics Inc., Nektar Therapeutics Inc.

North America was the largest region in the metastatic breast cancer treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global metastatic breast cancer treatment market during the forecast period. The regions covered in the metastatic breast cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the metastatic breast cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The metastatic breast cancer treatment market includes revenues earned by entities by immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Metastatic Breast Cancer Treatment Market Characteristics

3. Metastatic Breast Cancer Treatment Market Trends And Strategies

4. Metastatic Breast Cancer Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Metastatic Breast Cancer Treatment Market Size and Growth

  • 5.1. Global Metastatic Breast Cancer Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Metastatic Breast Cancer Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Metastatic Breast Cancer Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Metastatic Breast Cancer Treatment Market Segmentation

  • 6.1. Global Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Radiation Therapy
  • Biologic Targeted Therapy
  • Breast Surgery
  • Hormone Therapy
  • 6.2. Global Metastatic Breast Cancer Treatment Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small Molecule
  • Gene Therapy
  • 6.3. Global Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.4. Global Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Other End-Users

7. Metastatic Breast Cancer Treatment Market Regional And Country Analysis

  • 7.1. Global Metastatic Breast Cancer Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Metastatic Breast Cancer Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Metastatic Breast Cancer Treatment Market

  • 8.1. Asia-Pacific Metastatic Breast Cancer Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Metastatic Breast Cancer Treatment Market

  • 9.1. China Metastatic Breast Cancer Treatment Market Overview
  • 9.2. China Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Metastatic Breast Cancer Treatment Market

  • 10.1. India Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Metastatic Breast Cancer Treatment Market

  • 11.1. Japan Metastatic Breast Cancer Treatment Market Overview
  • 11.2. Japan Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Metastatic Breast Cancer Treatment Market

  • 12.1. Australia Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Metastatic Breast Cancer Treatment Market

  • 13.1. Indonesia Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Metastatic Breast Cancer Treatment Market

  • 14.1. South Korea Metastatic Breast Cancer Treatment Market Overview
  • 14.2. South Korea Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Metastatic Breast Cancer Treatment Market

  • 15.1. Western Europe Metastatic Breast Cancer Treatment Market Overview
  • 15.2. Western Europe Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Metastatic Breast Cancer Treatment Market

  • 16.1. UK Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Metastatic Breast Cancer Treatment Market

  • 17.1. Germany Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Metastatic Breast Cancer Treatment Market

  • 18.1. France Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Metastatic Breast Cancer Treatment Market

  • 19.1. Italy Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Metastatic Breast Cancer Treatment Market

  • 20.1. Spain Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Metastatic Breast Cancer Treatment Market

  • 21.1. Eastern Europe Metastatic Breast Cancer Treatment Market Overview
  • 21.2. Eastern Europe Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Metastatic Breast Cancer Treatment Market

  • 22.1. Russia Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Metastatic Breast Cancer Treatment Market

  • 23.1. North America Metastatic Breast Cancer Treatment Market Overview
  • 23.2. North America Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Metastatic Breast Cancer Treatment Market

  • 24.1. USA Metastatic Breast Cancer Treatment Market Overview
  • 24.2. USA Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Metastatic Breast Cancer Treatment Market

  • 25.1. Canada Metastatic Breast Cancer Treatment Market Overview
  • 25.2. Canada Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Metastatic Breast Cancer Treatment Market

  • 26.1. South America Metastatic Breast Cancer Treatment Market Overview
  • 26.2. South America Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Metastatic Breast Cancer Treatment Market

  • 27.1. Brazil Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Metastatic Breast Cancer Treatment Market

  • 28.1. Middle East Metastatic Breast Cancer Treatment Market Overview
  • 28.2. Middle East Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Metastatic Breast Cancer Treatment Market

  • 29.1. Africa Metastatic Breast Cancer Treatment Market Overview
  • 29.2. Africa Metastatic Breast Cancer Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Metastatic Breast Cancer Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Metastatic Breast Cancer Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Metastatic Breast Cancer Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Metastatic Breast Cancer Treatment Market Competitive Landscape
  • 30.2. Metastatic Breast Cancer Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AstraZeneca plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Gilead Science Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Eli Lilly & Co.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Metastatic Breast Cancer Treatment Market Competitive Benchmarking

32. Global Metastatic Breast Cancer Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Metastatic Breast Cancer Treatment Market

34. Metastatic Breast Cancer Treatment Market Future Outlook and Potential Analysis

  • 34.1 Metastatic Breast Cancer Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Metastatic Breast Cancer Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Metastatic Breast Cancer Treatment Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer